Pancreatic carcinoma (PDAC) carries significant morbidity and mortality and remains one of the most difficult malignancies to treat. Individual patient and tumor factors need to be taken into account to provide an optimal, personalized approach. The following article evaluates the response of pancreatic ductal carcinoma after neoplastic adjuvant therapy